As of 2026-04-13, the Relative Valuation of Taysha Gene Therapies Inc (TSHA) is (8.70) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.49 USD, the upside of Taysha Gene Therapies Inc based on Relative Valuation is -293.9%.
The range of the Relative Valuation is (7.86) - (9.16) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 19.8x - 25.2x | 22.4x |
| Forward P/E multiples | 19.7x - 23.0x | 21.4x |
| Fair Price | (7.86) - (9.16) | (8.70) |
| Upside | -275.1% - -304.0% | -293.9% |
| Date | P/E |
| 2026-04-10 | -11.28 |
| 2026-04-09 | -11.64 |
| 2026-04-08 | -11.43 |
| 2026-04-07 | -11.49 |
| 2026-04-06 | -11.69 |
| 2026-04-02 | -10.98 |
| 2026-04-01 | -10.83 |
| 2026-03-31 | -11.23 |
| 2026-03-30 | -10.23 |
| 2026-03-27 | -10.23 |
| 2026-03-26 | -10.86 |
| 2026-03-25 | -11.51 |
| 2026-03-24 | -10.38 |
| 2026-03-23 | -11.41 |
| 2026-03-20 | -11.06 |
| 2026-03-19 | -11.46 |
| 2026-03-18 | -11.18 |
| 2026-03-17 | -11.49 |
| 2026-03-16 | -11.38 |
| 2026-03-13 | -11.28 |
| 2026-03-12 | -11.59 |
| 2026-03-11 | -11.35 |
| 2026-03-10 | -11.49 |
| 2026-03-09 | -11.54 |
| 2026-03-06 | -11.49 |
| 2026-03-05 | -11.28 |
| 2026-03-04 | -11.66 |
| 2026-03-03 | -11.38 |
| 2026-03-02 | -11.38 |
| 2026-02-27 | -11.38 |
| 2026-02-26 | -11.49 |
| 2026-02-25 | -11.74 |
| 2026-02-24 | -12.29 |
| 2026-02-23 | -12.16 |
| 2026-02-20 | -11.81 |
| 2026-02-19 | -12.04 |
| 2026-02-18 | -11.69 |
| 2026-02-17 | -11.51 |
| 2026-02-13 | -11.43 |
| 2026-02-12 | -11.69 |
| 2026-02-11 | -11.71 |
| 2026-02-10 | -11.26 |
| 2026-02-09 | -11.59 |
| 2026-02-06 | -11.59 |
| 2026-02-05 | -11.08 |
| 2026-02-04 | -11.41 |
| 2026-02-03 | -11.86 |
| 2026-02-02 | -11.71 |
| 2026-01-30 | -11.33 |
| 2026-01-29 | -11.49 |